A selective MT2 melatonin receptor antagonist, 4-phenyl-2-propionamidotetra
lin (4P-PDOT), was prepared as a tritium-labelled compound with high specif
ic activity and radiochemical purity. Catalytic hydrogenation of a unique v
inyl bromo precursor 10 was used to introduce the tritium.